ANNX vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FDMT Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to 4D Molecular Therapeutics, Inc. Common Stock (FDMT) driven by superior Momentum & Technical, Options & Structure while ANNX counters with relative strength in Growth & Margin. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, ANNX sits in BREAKDOWN (40th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANNX | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $757.3M | $669.3M | Larger Scale | ANNX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | 0.0% | -222.7% | Higher Margin | ANNX |
| Net Profit Margin Profitability | 0.0% | -208.6% | Higher Margin | ANNX |
| Return on Equity (ROE) Capital Efficiency | -130.8% | -56.7% | Higher ROE | FDMT |
| 52-Week Range Position Momentum | 22% ($3โ$7) | 47% ($7โ$17) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.68ฮฒ ยท 62% Vol | 1.89ฮฒ ยท 90% Vol | Lower Realized Risk | ANNX |
| Unified Institutional Score Composite Signal | 44.6 / 100 (HOLD) | 51.3 / 100 (HOLD) | Higher Composite | FDMT |